Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 277 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Malignant Melanoma
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Springdale, Arkansas • San Francisco, California • Hackensack, New Jersey + 2 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

North American Prodromal Synucleinopathy Consortium Stage 2

NCT05826457
Conditions
REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Redwood City, California • Atlanta, Georgia + 5 more
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more
Conditions
Dementia, Alzheimer Disease, Vascular Dementia, Frontotemporal Dementia, Lewy Body Dementia, Mixed Dementia
Interventions
Not listed
Lead sponsor
HealthMode Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Tucson, Arizona • New York, New York
Conditions
Advanced/Metastatic Solid Tumors
Interventions
Selumetinib, Pembrolizumab
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Duarte, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Neural Disorders

NCT02761707
Conditions
Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor, Multiple System Atrophy, Drug Induced Parkinson's Disease, Diffuse Lewy Body Disease, Myasthenia Gravis, Spinal Cord Injuries
Interventions
Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation, Peripheral Nerve Stimulation
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Solid Tumors, Advanced Solid Tumors
Interventions
MK-0472, Pembrolizumab, MK-1084
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Louisville, Kentucky • Hackensack, New Jersey + 1 more
Conditions
Biliary Tract Carcinoma
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab 200 mg, Paclitaxel 45 mg/m^2, Carboplatin AUC6, Cisplatin 75 mg/m^2, Pemetrexed 500 mg/m^2, Thoracic Radiation Therapy (TRT), Paclitaxel 200 mg/m^2, Carboplatin AUC2
Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
10
States / cities
Santa Rosa, California • Evanston, Illinois • Fort Wayne, Indiana + 7 more
Conditions
Alzheimer Disease, Frontotemporal Degeneration (FTD), Lewy Body Dementia (LBD), Vascular Contributions to Cognitive Impairment and Dementia (VCID), Mixed Etiology Dementias (MED), Mild Cognitive Impairment (MCI)
Interventions
Problem Solving Training
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
College Station, Texas • Dallas, Texas • Edinburg, Texas
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Lenvatinib, Pembrolizumab, Docetaxel, Capecitabine, Paclitaxel, Cetuximab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
55
States / cities
Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more
Conditions
Advanced Melanoma
Interventions
lenvatinib, pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Chandler, Arizona • Santa Monica, California • Park Ridge, Illinois + 3 more
Conditions
Parkinson Disease, Dementia, Lewy Body, Delirium
Interventions
Music therapy intervention, Standard Care (in control arm)
Behavioral · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Lewy Body Disease, Parkinson Disease
Interventions
E2027
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Sun City, Arizona • Atlantis, Florida • Miami, Florida + 10 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection
Diagnostic Test · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia

NCT01059877
Conditions
Dementia
Interventions
1072nm infrared Photobiomodulation, Photobiomodulation SIMULATED
Device
Lead sponsor
Quietmind Foundation
Other
Eligibility
50 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Plymouth Meeting, Pennsylvania
Conditions
Head and Neck Neoplasms
Interventions
Pembrolizumab, Placebo, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy, Standard Fractionation (SFX) Radiotherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
24
States / cities
Los Angeles, California • San Francisco, California • Santa Rosa, California + 21 more
Conditions
Advanced Solid Tumors
Interventions
IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig, SC rilvegostomig + rHu
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia
Conditions
Parkinson Disease
Interventions
Lithium
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
45 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Williamsville, New York
Conditions
Small Cell Lung Cancer
Interventions
Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
35
States / cities
Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more
Conditions
Esophageal Neoplasms
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
12
States / cities
West Los Angeles, California • Chicago, Illinois • Westwood, Kansas + 9 more
Conditions
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD), Lewy Body Disease
Interventions
Not listed
Lead sponsor
BioSensics
Industry
Eligibility
40 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Lutherville, Maryland • Boston, Massachusetts
Conditions
Neoplasm
Interventions
preladenant, pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Grand Rapids, Michigan